# Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder

> **NCT06830044** · PHASE3 · RECRUITING · sponsor: **Vanda Pharmaceuticals** · enrollment: 500 (estimated)

## Conditions studied

- Major Depressive Disorder (MDD)

## Interventions

- **DRUG:** Milsaperidone
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06830044
- **Lead sponsor:** Vanda Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-03
- **Primary completion:** 2028-03
- **Final completion:** 2028-03
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2026-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06830044

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06830044, "Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT06830044. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*